BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25247751)

  • 1. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
    Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
    J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
    Sepe V; Renga B; Festa C; D'Amore C; Masullo D; Cipriani S; Di Leva FS; Monti MC; Novellino E; Limongelli V; Zampella A; Fiorucci S
    J Med Chem; 2014 Sep; 57(18):7687-701. PubMed ID: 25162837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
    Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
    J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
    Gioiello A; Macchiarulo A; Carotti A; Filipponi P; Costantino G; Rizzo G; Adorini L; Pellicciari R
    Bioorg Med Chem; 2011 Apr; 19(8):2650-8. PubMed ID: 21459580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
    D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V
    J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling.
    Cipriani S; Renga B; D'Amore C; Simonetti M; De Tursi AA; Carino A; Monti MC; Sepe V; Zampella A; Fiorucci S
    PLoS One; 2015; 10(7):e0129866. PubMed ID: 26177448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties.
    Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists.
    Sepe V; Festa C; Renga B; Carino A; Cipriani S; Finamore C; Masullo D; Del Gaudio F; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jan; 6():19008. PubMed ID: 26740187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists.
    Yu DD; Sousa KM; Mattern DL; Wagner J; Fu X; Vaidehi N; Forman BM; Huang W
    Bioorg Med Chem; 2015 Apr; 23(7):1613-28. PubMed ID: 25735208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marine sponge steroids as nuclear receptor ligands.
    Fiorucci S; Distrutti E; Bifulco G; D'Auria MV; Zampella A
    Trends Pharmacol Sci; 2012 Nov; 33(11):591-601. PubMed ID: 23000093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
    Pellicciari R; Sato H; Gioiello A; Costantino G; Macchiarulo A; Sadeghpour BM; Giorgi G; Schoonjans K; Auwerx J
    J Med Chem; 2007 Sep; 50(18):4265-8. PubMed ID: 17685603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
    Pellicciari R; Passeri D; De Franco F; Mostarda S; Filipponi P; Colliva C; Gadaleta RM; Franco P; Carotti A; Macchiarulo A; Roda A; Moschetta A; Gioiello A
    J Med Chem; 2016 Oct; 59(19):9201-9214. PubMed ID: 27652492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
    Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.